# EDGAR Filing Document

**Accession Number:** 0001023549
**File Stem:** 0001213900-26-070771
**Filing Date:** 2026-6
**Character Count:** 2570
**Document Hash:** 482c8b26493c8ff9319ac2338cbc71ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-070771.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001213900-26-070771

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260622

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XTL BIOPHARMACEUTICALS LTD
- **CENTRAL INDEX KEY:** 0001023549
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36000
- **FILM NUMBER:** 261108528

**BUSINESS ADDRESS:**
- **STREET 1:** XTL BIOPHARMACEUTICALS LTD
- **STREET 2:** C/O ALSTON & BIRD LLP, 90 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 972 9 955 7080

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN-GURION ST.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5112001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of June 2026

Commission File Number: 001-36000

**XTL Biopharmaceuticals Ltd.** 

(Exact name of Registrant as specified in its charter)

**26 Ben-Gurion St.**

**Ramat Gan, 5112001, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 22, 2026, XTL Biopharmaceuticals Ltd. (the "Company") convened an Extraordinary General Meeting of Shareholders (the "Extraordinary General Meeting"). However, the Extraordinary General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Extraordinary General Meeting will be reconvened on Monday, June 29, 2026 at 4:00 p.m., Israel time, at the offices of the Company's attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **XTL Biopharmaceuticals Ltd.** |
| Date: June 22, 2026 | */s/* Noam Band |
|  | Noam Band<br> Chief Executive Officer |

---